These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 26240494)
1. Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea. Kim SH; Seo HK; Shin HC; Chang SJ; Yun S; Joo J; Ku JH; Kim HS; Jeon HG; Jeong BC; Jeong IG; Kang SH; Hong B; J Korean Med Sci; 2015 Aug; 30(8):1150-6. PubMed ID: 26240494 [TBL] [Abstract][Full Text] [Related]
2. Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands. Hermans TJN; Fransen van de Putte EE; Horenblas S; Lemmens V; Aben K; van der Heijden MS; Beerepoot LV; Verhoeven RH; van Rhijn BWG Eur J Cancer; 2016 Feb; 54():18-26. PubMed ID: 26707593 [TBL] [Abstract][Full Text] [Related]
3. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710 [TBL] [Abstract][Full Text] [Related]
4. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530 [TBL] [Abstract][Full Text] [Related]
5. Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice. Dogan S; Hennig M; Frank T; Struck JP; Cebulla A; Salem J; Borgmann H; Klatte T; Merseburger AS; Kramer M; Hofbauer SL Urol Int; 2018; 101(1):25-30. PubMed ID: 29510388 [TBL] [Abstract][Full Text] [Related]
6. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024 [TBL] [Abstract][Full Text] [Related]
7. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998 [TBL] [Abstract][Full Text] [Related]
8. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Darwish C; Sparks A; Amdur R; Reddy A; Whalen M Urology; 2020 Dec; 146():168-176. PubMed ID: 32866509 [TBL] [Abstract][Full Text] [Related]
9. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. Alvaeus J; Rosenblatt R; Johansson M; Alamdari F; Jakubczyk T; Holmström B; Hemdan T; Huge Y; Aljabery F; Gabrielsson S; Riklund K; Winqvist O; Sherif A World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442 [TBL] [Abstract][Full Text] [Related]
10. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752 [No Abstract] [Full Text] [Related]
11. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341 [TBL] [Abstract][Full Text] [Related]
12. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889 [TBL] [Abstract][Full Text] [Related]
13. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239 [TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
15. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy. Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449 [No Abstract] [Full Text] [Related]
16. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657 [TBL] [Abstract][Full Text] [Related]
17. The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis. Liu W; Tian J; Zhang S; Yang E; Shen H; Li F; Li K; Zhang T; Wang H; Svatek RS; Rodriguez R; Wang Z Minerva Urol Nephrol; 2021 Apr; 73(2):144-153. PubMed ID: 31920065 [TBL] [Abstract][Full Text] [Related]
18. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866 [TBL] [Abstract][Full Text] [Related]
19. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
20. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU; Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]